Structure-activity study of the interaction of bioreductive benzoquinone alkylating agents with DNA topoisomerase II

Cancer Chemotherapy and Pharmacology

Volumn 57, Issue 2, 2006, Pages 221-233

  Hasinoff, Brian B ^a   Wu, Xing ^a   Begleiter, Asher ^b   Guziec, Lynn J ^c   Guziec Jr , Frank ^c   Giorgianni, Angela ^a   Yang, Shaohua ^a   Jiang, Yu ^a   Yalowich, Jack C ^d  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c SOUTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Bioreductive alkylating agents; Cytochrome P450 reductase; DNA; EPR; Quinone; Topoisomerase II

Indexed keywords

ALKYLATING AGENT; BENZOQUINONE MUSTARD; CYSTEINE; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); GLUTATHIONE;

AGAR GEL ELECTROPHORESIS; ANIMAL CELL; ARTICLE; CELL ACTIVITY; CELL GROWTH; CELL NUCLEUS; COMPLEX FORMATION; CORRELATION ANALYSIS; DNA ADDUCT; DNA CLEAVAGE; DNA CROSS LINKING; DNA DAMAGE; DNA PROTEIN COMPLEX; DRUG ACTIVITY; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; EVALUATION; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; MICHAEL ADDITION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

ALKYLATING AGENTS; ANIMALS; BENZOQUINONES; CELL PROLIFERATION; CHO CELLS; CRICETINAE; DNA ADDUCTS; DNA DAMAGE; DNA TOPOISOMERASES, TYPE II; DRUG INTERACTIONS; ELECTROPHORESIS, AGAR GEL; LEUKEMIA; OXIDATIVE STRESS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 28844482331     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-005-0040-5     Document Type: Article

References (45)

1. Alt C, Eyer P (1998) Ring addition of the α-amino group of glutathione increases the reactivity of benzoquinone thioethers. Chem Res Toxicol 11:1223-1233
2. Amaro AR, Oakley GG, Bauer U, Spielmann HP, Robertson LW (1996) Metabolic activation of PCBs to quinones: reactivity toward nitrogen and sulfur nucleophiles and influence of superoxide dismutase. Chem Res Toxicol 9:623-629
3. Bailey SM, Lewis AD, Patterson LH, Fisher GR, Knox RJ, Workman P (2001) Involvement of NADPH: cytochrome P450 reductase in the activation of indoloquinone EO9 to free radical and DNA damaging species. Biochem Pharmacol 62:461-468
4. Baker RK, Kurz EU, Pyatt DW, Irons RD, Kroll DJ (2001) Benzene metabolites antagonize etoposide-stabilized cleavable complexes of DNA topoisomerase IIα. Blood 98:830-833
5. Barnabè N, Hasinoff BB (2001) High-throughput fluorescence flow injection topoisomerase II inhibition assay. J Chromatogr B Biomed Sci Appl 760:263-269
6. Barnabè N, Zastre J, Venkataram S, Hasinoff BB (2002) Deferiprone protects against doxorubicin-induced myocyte cytotoxicity. Free Radic Biol Med 33:266-275
7. Bender RP, Lindsey RH Jr, Burden DA, Osheroff N (2004) N-acetyl-p-benzoquinone imine, the toxic metabolite of acetaminophen, is a topoisomerase II poison. Biochemistry 43:3731-3739
8. Bolton JL, Trush MA, Penning TM, Dryhurst G, Monks TJ (2000) Role of quinones in toxicology. Chem Res Toxicol 13:135-160
9. Burden DA, Froelich-Ammon SJ, Osheroff N (2001) Topisomerase II-mediated cleavage of plasmid DNA. Methods Mol Biol 95:283-289
10. Chen H, Eastmond DA (1995) Topoisomerase inhibition by phenolic metabolites: a potential mechanism for benzene's clastogenic effects. Carcinogenesis 16:2301-2307
11. Fattman C, Allan WP, Hasinoff BB, Yalowich JC (1996) Collateral sensitivity to the bisdioxopiperazine dexrazoxane (ICRF-187) in etoposide (VP-16) resistant human leukemia K562 cells. Biochem Pharmacol 52:635-642
12. Fortune JM, Osheroff N (2000) Topoisomerase II as a target for anticancer drugs: When enzymes stop being nice. Prog Nucleic Acid Res Mol Biol 64:221-253
13. Fourie J, Guziec F Jr, Guziec L, Monterrosa C, Fiterman DJ, Begleiter A (2004) Structure-activity study with bioreductive benzoquinone alkylating agents: effects on DT-diaphorase-mediated DNA crosslink and strand break formation in relation to mechanisms of cytotoxicity. Cancer Chemother Pharmacol 53:191-203
14. Fourie J, Oleschuk CJ, Guziec F Jr, Guziec L, Fiterman DJ, Monterrosa C, Begleiter A (2002) The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase. Cancer Chemother Pharmacol 49:101-110
15. Frantz CE, Chen H, Eastmond DA (1996) Inhibition of human topoisomerase II in vitro by bioactive benzene metabolites. Environ Health Perspect 104 Suppl 6:1319-1323
16. Frydman B, Marton LJ, Sun JS, Neder K, Witiak DT, Liu AA, Wang HM, Mao Y, Wu HY, Sanders MM, Liu LF (1997) Induction of DNA topoisomerase II-mediated DNA cleavage by β-lapachone and related naphthoquinones. Cancer Res 57:620-627
17. Gantchev TG, Hunting DJ (1997) Inhibition of the topoisomerase II-DNA cleavable complex by the ortho-quinone derivative of the antitumor drug etoposide (VP-16). Biochem Biophys Res Comm 237:24-27
18. Gantchev TG, Hunting DJ (1998) The ortho-quinone metabolite of the anticancer drug etoposide (VP-16) is a potent inhibitor of the topoisomerase II/DNA cleavable complex. Mol Pharmacol 53:422-428
19. 2(levrazoxane), of the topoisomerase II inhibitors dexrazoxane (ICRF-187) and levrazoxane (ICRF-186). J Inorg Biochem 98:616-624
20. Hasinoff BB, Kuschak TI, Yalowich JC, Creighton AM (1995) A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane). Biochem Pharmacol 50:953-958
21. Hasinoff BB, Kozlowska H, Creighton AM, Allan WP, Thampatty P, Yalowich JC (1997) Mitindomide is a catalytic inhibitor of DNA topoisomerase II that acts at the bisdioxopiperazine binding site. Mol Pharmacol 52:839-845
22. Hasinoff BB, Kuschak TI, Creighton AM, Fattman CL, Allan WP, Thampatty P, Yalowich JC (1997) Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II. Biochem Pharmacol 53:1843-1853
23. Hasinoff BB, Wu X, Krokhin OV, Ens W, Standing KG, Nitiss JL, Sivaram T, Giorgianni A, Yang S, Jiang Y, Yalowich JC (2005) Biochemical and proteomics approaches to characterize topoisomerase IIα cysteines and DNA as targets responsible for cisplatin-induced inhibition of topoisomerase IIα. Mol Pharmacol 67:937-947
24. Hutt AM, Kalf GF (1996) Inhibition of human DNA topoisomerase II by hydroquinone and p-benzoquinone, reactive metabolites of benzene. Environ Health Perspect 104 (Suppl 6):1265-1269
25. Jensen LH, Renodon-Corniere A, Wessel I, Langer SW, Sokilde B, Carstensen EV, Sehested M, Jensen PB (2002) Maleimide is a potent inhibitor of topoisomerase II in vitro and in vivo: a new mode of catalytic inhibition. Mol Pharmacol 61:1235-1243
26. Li TK, Liu LF (2001) Tumor cell death induced by topoisomerase-targeting drugs. Annu Rev Pharmacol Toxicol 41:53-77
27. Lindsey RH Jr, Bromberg KD, Felix CA, Osheroff N (2004) 1,4-Benzoquinone is a topoisomerase II poison. Biochemistry 43:7563-7574
28. Makarova AN, Berlin AY (1967) Bis(2-chloroethyl)amino-p-benzoquinones and their derivatives. J Gen Chem USSR 37:595-560
29. Mekapati SB, Hansch C (2002) On the parametrization of the toxicity of organic chemicals to tetrahymena pyriformis. The problem of establishing a uniform activity. J Chem Inf Comput Sci 42:956-961
30. Monks TJ, Jones DC (2002) The metabolism and toxicity of quinones, quinonimines, quinone methides, and quinone-thioethers. Curr Drug Metab 3:425-438
31. Neder K, Marton LJ, Liu LF, Frydman B (1998) Reaction of beta-lapachone and related naphthoquinones with 2-mercaptoethanol: a biomimetic model of topoisomerase II poisoning by quinones. Cell Mol Biol (Noisy-le-grand) 44:465-474
32. O'Brien PJ (1991) Molecular mechanisms of quinone cytotoxicity. Chem Biol Interact 80:1-41
33. Ollinger K, Brunmark A (1991) Effect of hydroxy substituent position on 1,4-naphthoquinone toxicity to rat hepatocytes. J Biol Chem 266:21496-21503
34. Powis G (1989) Free radical formation by antitumor quinones. Free Radic Biol Med 6:63-101
35. Ritke MK, Yalowich JC (1993) Altered gene expression in human leukemia K562 cells selected for resistance to etoposide. Biochem Pharmacol 46:2007-2020
36. Ritke MK, Allan WP, Fattman C, Gunduz NN, Yalowich JC (1994) Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells. Mol Pharmacol 46:58-66
37. Ritke MK, Roberts D, Allan WP, Raymond J, Bergoltz VV, Yalowich JC (1994) Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukemia K562 cells. Br J Cancer 69:687-697
38. Sehested M, Wessel I, Jensen LH, Holm B, Oliveri RS, Kenwrick S, Creighton AM, Nitiss JL, Jensen PB (1998) Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: A Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines. Cancer Res 58:1460-1468
39. Siraki AG, Chan TS, O'Brien PJ (2004) Application of quantitative structure-toxicity relationships for the comparison of the cytotoxicity of 14 p-benzoquinone congeners in primary cultured rat hepatocytes versus PC12 cells. Toxicol Sci 81:148-159
40. Swallow AJ (1982) Physical chemistry of semiquinones. In: Trumpower BL (ed) Function of quinones in energy conserving systems. New York: Academic, pp 59-72
41. Wang H, Mao Y, Chen AY, Zhou N, LaVoie EJ, Liu LF (2001) Stimulation of topoisomerase II-mediated DNA damage via a mechanism involving protein thiolation. Biochemistry 40:3316-3323
42. Wilson I, Wardman P, Lin TS, Sartorelli AC (1987) Reactivity of thiols towards derivatives of 2- and 6-methyl-1,4-naphthoquinone bioreductive alkylating agents. Chem Biol Interact 61:229-240
43. Workman P, Stratford IJ (1993) The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metastasis Rev 12:73-82
44. Yalowich JC, Thampatty P, Allan WP, Chee G-L, Hasinoff BB (1998) Acquired resistance to ICRF-187 (dexrazoxane) in a CHO cell line is associated with a point mutation in DNA topoisomerase IIα (topo II) and decreased drug-induced DNA-enzyme complexes. Proc Am Assoc Cancer Res 39:375
45. Zhu BZ, Zhao HT, Kalyanaraman B, Frei B (2002) Metal-independent production of hydroxyl radicals by halogenated quinones and hydrogen peroxide: an ESR spin trapping study. Free Radic Biol Med 32:465-473